Precision Diabetes, Inc.

Precision Diabetes, Inc. is an emerging leader in precision medicine for diabetes, headquartered in Raleigh, North Carolina (Research Triangle Park). The company develops and markets novel diabetes biomarkers and diagnostic tests that span diabetes risk assessment through complication detection. Primary product is GlycoMark, a proprietary diabetes biomarker test for which Precision Diabetes holds exclusive distribution rights across the United States, Europe, Australia, Asia-Pacific, Middle East, and Mexico. GlycoMark is validated as a prediabetes biomarker and novel indicator of SGLT-2 inhibitor adherence; recent clinical data suggests utility in COVID-19 severity assessment. The company also partners with Patia Europe to distribute DIABETESpredict (type 2 diabetes genetic testing) and Matergen (gestational diabetes genetic testing) in the U.S. market. Precision Diabetes maintains a strategic partnership with DxGen Corp. to commercialize a point-of-care diabetes testing analyzer. The portfolio addresses both clinical laboratory and point-of-care testing modalities, serving endocrinology, primary care, and hospital laboratory markets. Company demonstrates active clinical research engagement, with publications and presentations at major conferences including the American Diabetes Association.